Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 2433Neoplasms 1842Carcinoma, Non-Small-Cell Lung 1609Prostatic Neoplasms 1312Colorectal Neoplasms 1144Lung Neoplasms 991Neoplasm Metastasis 835Multiple Myeloma 800Leukemia, Myeloid, Acute 778Ovarian Neoplasms 685Pancreatic Neoplasms 671Melanoma 667Squamous Cell Carcinoma of Head and Neck 592Carcinoma, Hepatocellular 570Recurrence 568Brain Neoplasms 528Glioblastoma 519Stomach Neoplasms 503Head and Neck Neoplasms 502Triple Negative Breast Neoplasms 473Lymphoma 461Uterine Cervical Neoplasms 457Carcinoma, Renal Cell 429Precursor Cell Lymphoblastic Leukemia-Lymphoma 421Lymphoma, Non-Hodgkin 390Endometrial Neoplasms 386Sarcoma 369Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 356Lymphoma, Follicular 356

Interventions

Specimen Handling 1Rituximab 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Classic Follicular Lymphoma × 1 year × Clear all
NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡